Quality of life issues associated with antipsychotic-induced weight gain

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 3, Issue 5, 2003, Pages 651-659

  Masand, Prakash S ^a   Gupta, Sanjay ^b,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c Olean General Hospital   (United States)

Author keywords

Antipsychotic; Aripiprazole; Bodyweight gain; Clozapine; Diabetes mellitus; Obesity; Olanzapine; Quality of life; Risperidone; Ziprasidone

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHOLESTEROL; CLOZAPINE; DOPAMINE 2 RECEPTOR; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; INSULIN; LAMOTRIGINE; LITHIUM; LOW DENSITY LIPOPROTEIN; METFORMIN; MOLINDONE; NIZATIDINE; OLANZAPINE; QUETIAPINE; REBOXETINE; RISPERIDONE; SEROTONIN 2C RECEPTOR; SERTINDOLE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; THIORIDAZINE; TOPIRAMATE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

ANTICHOLINERGIC EFFECT; ARTHRITIS; BODY WEIGHT; DIABETES MELLITUS; DIET THERAPY; DRUG INDUCED DISEASE; DYSLIPIDEMIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KINESIOTHERAPY; MENTAL DISEASE; MORBIDITY; MORTALITY; OBESITY; ORTHOSTATIC HYPOTENSION; PATIENT COUNSELING; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; TREATMENT OUTCOME;

EID: 0142155069     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.3.5.651     Document Type: Review

References (81)

1. Sarlio-Lahteenkorva S, Stunkard A, Rissanan A. Psychosocial factors and quality of life in obesity. Int. J. Obes. Relat. Metab. Disord. 19(Suppl. 6), S1-S5 (1995).
2. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 286, 1195-1200 (2001).
3. Kawachi I. Physical and psychological consequences of weight gain. J. Clin. Psychiatry 60(Suppl. 21), 5-9 (1999).
4. National Institutes of Health. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the Evidence Report. Obes. Res. 6(Suppl. 2), S51-S209 (1998).
5. Fontaine KR, Barofsky I. Obesity and health-related quality of life. Obes. Rev. 2, 173-182 (2001).
6. Yancy WS Jr, Olsen MK, Westman EC, Bosworth HB, Edelman D. Relationship between obesity and health-related quality of life in men. Obes. Res. 10, 1057-1062 (2002).
7. Allison DB, Fontaine KR, Heo M et al. The distribution of body mass index among individuals with and without schizophrenia. J. Clin. Psychiatry 60, 215-220 (1999).
8. Casey DE. The relationship of pharmacology to side effects. J. Clin. Psychiatry 58(Suppl. 10), 55-62 (1997).
9. Collaborative Working Group on Clinical Trials Evaluations. Assessment of EPS and tardive dyskinesia in clinical trials. J. Clin. Psychiatry 59(Suppl. 12), 23-27 (1998).
10. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J. Clin. Psychiatry 62(Suppl. 7), 22-31 (2001).
11. Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156, 1686-1696 (1999).
12. Masand PS, Gupta S. Long-term adverse effects of novel antipsychotics. J. Psychiatric Pract. 6, 299-309 (2000).
13. Glick ID, Murray SR, Vasudevan P, Marder SR, Hu RJ. Treatment with atypical antipsychotics: new indications and new populations. J. Psychiatr. Res. 35, 187-191 (2001).
14. Collaborative Working Group on Clinical Trials Evaluations. Adverse effects of the atypical antipsychotics. J. Clin. Psychiatry 59(Suppl. 12), 17-22 (1998).
15. Baptista T. Body weight induced by antipsychotic drugs: mechanisms and management. Acta. Psychiatr. Scan. 100, 3-16 (1999).
16. Kalucy RS. Drug-induced weight gain. Drugs 19, 268-278 (1980).
17. Kurzthaler D, Fleischhacker WW. The clinical implications of weight gain in schizophrenia. J. Clin. Psychiatry 62(Suppl. 7), 32-37 (2001).
18. Perkins DO. Adherence to antipsychotic medications. J. Clin. Psychiatry 60(Suppl. 21), 25-30 (1999).
19. Henderson DC, Cagliero E, Gray C et al. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: a 5 year naturalistic study. Am. J. Psychiatry 157, 975-981 (2000).
20. Csernansky JG, Mahmoud R, Brenner R for the Risperidone-USA-70 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 346, 16-22 (2002).
21. Geodon prescribing information. Pfizer Inc, NY, USA, June (2002).
22. Jody D, Saha AR, Iwamoto T et al. Meta-analysis of weight effects with aripiprazole. Int. J. Neuropsychopharmacol. 5 (Suppl. 1), S186 (2002).
23. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related healths factors in schizophrenia. J. Clin. Psychiatry 62, 92-100 (2001).
24. Henderson DC. Clinical experience with insulin resistance, diabetic ketoacidosis and Type 2 diabetes mellitus in patients treated with atypical antipsychotic agents. J. Clin. Psychiatry 62(Suppl. 27), 10-14 (2001).
25. Baptista T, Kin NM, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35, 205-219 (2002).
26. Wang GJ, Volkow ND, Logan J et al. Brain dopamine and obesity. Lancet 357, 354-357 (2001).
27. Reynolds GP, Zhang Z, Zhang X. Association of antipsychotic drug induced weight gain with a 5HT2C receptor gene polymorphism. Lancet 359, 2086-2087 (2002).
28. Meyer J. Effects of atypical antipsychotics on weight and serum lipids. J. Clin. Psychiatry 62(Suppl. 27), 27-34 (2001).
29. Kroeze WK, Hufeisen SJ, Popadak BA et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28, 519-526 (2003).
30. Masand PS. Relative weight gain among antipsychotics. J. Clin. Psychiatry 60, 706-708 (1999).
31. Wetterling T. Bodyweight gain with atypical antipsychotics: a comparative review. Drug Saf. 24, 59-73 (2001).
32. Schmidt AW, Lebel LA, Howard, HR Jr, Zorn, SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur. J. Pharmacol. 25, 197-201 (2001).
33. Ackerman S, Nolan LJ. Bodyweight gain induced by psychotropic drugs: incidence, mechanisms and management. CNS Drugs 9, 135-151 (1998).
34. Masand PS. Weight gain associated with psychotropic drugs. Expert. Opin. Pharmacother. 1, 377-389 (2000).
35. Meyer JM. A retrospective comparison of weight, lipid and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J. Clin. Psychiatry 63, 4433-4525. (2002).
36. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am. J. Psychiatry 156, 1417-1420 (1999).
37. McKee HA, D'Arcy PF, Wilson PJ. Diabetes and schizophrenia: a preliminary study. J. Clin. Hosp. Pharm. 11, 297-299 (1986).
38. Mukherjee S, Decina P, Bocola V et al. Diabetes mellitus in schizophrenic patients. Compr. Psychiatry 37, 68-73 (1996).
39. Gupta S, Steinmeyer C, Frank B et al. Hyperglycemia and hyperlipidemia in real world patients on antipsychotic therapy. Am. J. Therapeutics (2003) (In Press).
40. Martina CMR, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 160, 284-289 (2003).
41. Dixon L, Weiden P, Delahanty J et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull. 26, 903-912 (2000).
42. Liebzeit K, Markowitz J, Caley C. New onset diabetes and atypical antipsychotics. Eur. Neuropsychopharmacol. 11, 25-32 (2001).
43. Henderson DC. Clozapine: diabetes mellitus, weight gain and lipid abnormalities. J. Clin. Psychiatry 62(Suppl. 23), 39-44 (2001).
44. Haupt D, Newcomer J. Hyperglycemia and antipsychotic medications. J. Clin. Psychiatry 62(Suppl. 27), 15-26 (2001).
45. Wirshing DA, Pierre JM, Eyeler J et al. Risperidone-associated new-onset diabetes. Biol. Psychiatry 50, 148-149 (2001).
46. Jin H, Meyer JM, Jeste D. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann. Clin. Psychiatry 14, 59-64 (2002).
47. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 22, 841-852 (2002).
48. Masand PS. Atypical Antipsychotics and DKA: Issues and Controversies. Thomson Professional Postgraduate Services. 1(2), 2002.
49. Wirshing DA, Spellberg BJ, Erhart SM et al. Novel antipsychotics and new-onset diabetes. Biol. Psychiatry 44, 778-783 (1998).
50. American Diabetes Association. Diabetic nephropathy. Diabetes Care 25(Suppl. 1), S85-S89 (2002).
51. American Diabetes Association. National standards for diabetes self-management education. Diabetes Care 25 (Suppl. 1), S140-S147 (2002).
52. Kannel WB, Brand N, Skinner JJ Jr, Dawber TR, McNamara PM. The relation of adiposity to blood pressure and development of hypertension: the Framingham study. Ann. Intern. Med. 67, 48-59 (1967).
53. Huang Z, Willett WC, Manson JE et al. Body weight, weight changes and risk for hypertension in women. Ann. Intern. Med. 128, 81-88 (1998).
54. Willett WC, Manson JE, Stampfer MJ et al. Weight, weight change and coronary heart disease in women: risk within the normal weight range. JAMA 273, 461-465 (1995).
55. Grundy SM, Becker D, Clark LT et al. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
56. Doering S, Muller E, Kopcke W et al. Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophr. Bull. 24, 419-429 (1998).
57. Buis W. Patients' opinions concerning side effects of depot neuroleptics. Am. J. Psychiatry 149, 844-845 (1992).
58. Gitlin MJ, Cochran SD, Jamison KR. Maintenance lithium treatment: side effects and compliance. J. Clin. Psychiatry 50, 127-131 (1989).
59. Angermeyer MC, Matschinger H. Neuroleptics and quality of life: a patient survey. Psychiatr. Prax. 27, 64-68 (2000).
60. Weiden PJ, Allison DB, Mackell JA, McDonnell D. Obesity as a risk factor for antipsychotic noncompliance. Presented at the 2000 Annual Meeting of the American Psychiatric Association, Chicago, IL, May 13-18 (2002).
61. Gortmaker SL, Must A, Perrin JM, Sobol AM, Dietz WH. Social and economic consequences of overweight in adolescence and young adulthood. N. Engl. J. Med. 329, 1008-1012 (1993).
62. Crocker J, Cornwell B, Major B. The stigma of overweight: affective consequences and attributional ambiguity. J. Pers. Soc. Psychol. 64, 60-70 (1993).
63. Rumpel C, Ingram DD, Harris TB et al. The association between weight change and psychological well-being in women. Int. J. Obes. 18, 179-183 (1994).
64. Sullivan M, Karlsson J, Sjostrom L et al. Swedish obese subjects (SOS) - an intervention study of obesity: baseline evaluation of health and psychosocial functioning in the first 1743 subjects examined. Int. J. Obes. Relat. Metab. Disord. 17, 503-512 (1993).
65. Fine JT, Colditz GA, Coakley EH et al. A prospective study of weight change and health-related quality of life in women. JAMA 282, 2136-2142 (1999).
66. Damush TM, Stump TE, Clark DO. Body mass index and 4-year change in health-related quality of life. J. Aging Health 14, 195-210 (2002).
67. Larsson U, Karlsson J, Sullivan M. Impact of overweight and obesity on health-related quality of life: a Swedish population study. Int. J. Relat. Metab. Disord. 26, 417-424 (2002).
68. Masand PS. Weight gain associated with atypical antipsychotics. J. Psychotic Dis. Rev. 2, 4-6 (1998).
69. Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 15, 537-551 (2001).
70. Masand PS, Berry SL. Switching antipsychotic therapies. Ann. Pharmacother. 34, 200-207 (2000).
71. Nguyen CT, Ortiz T, Franklin D et al. Nutritional education in minimizing weight gain with antipsychotic therapy. Proceedings of the American Psychiatric Association, LA, USA (2001).
72. Bustillo JR, Lauriello J, Parker K et al. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology 28, 527-529 (2003).
73. Poyurovsky M, Pashinian A, Gil-Ad I et al. Olanzapine-induced weight gain in patients with first episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am. J. Psychiatry 159, 1058-1060 (2002).
74. Poyurovsky M, Isaacs I, Fuchs C et al. Attentuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am. J. Psychiarty 160, 297-302 (2003).
75. Baptista T, Hernandez L, Alvarez L et al. Metformin in obesity associated with antipsychotic drug administration: a pilot study. J. Clin. Psychiatry 62, 653-654 (2001).
76. Morrison J, Cottingham E, Barton B. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am. J. Psychiatry 159, 655-657 (2002).
77. Floris M, Lejeune J, Deberdt W. Effect of amantadine on weight gain during olanzapine treatment. Eur. Neuropsychopharmacol. 11, 181-182 (2001).
78. Gupta S, Masand PS, Frank BL et al. Topiramate in bipolar and schizoaffective disorders: weight loss and efficacy. Primary Care Companion J. Clin. Psychiatry 2, 96-100 (2000).
79. Breier A. Tanaka Y, Roychowdhury S. Nizatidine ameliorates olanzapine treatment-related weight gain. International Congress on Schizophrenia Research, Indianapolis, IN, USA (2002).
80. Sacchetti E, Guarneri L, Bravi D. H2 antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol. Psychiatry 48, 167-168 (2000).
81. Werneke U, Taylor D, Sanders TA. Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int. Clin. Psychopharmacol. 17, 145-160 (2002).